CNR1 and mood disorder: In addition, the importance of the cannabinoid signaling in mood disorders is specifically highlighted by the severe increase in depressive and anxiety symptoms following administration of the CB1 antagonist appetite suppressant rimonabant in previously non-depressed human subjects (Christensen et al., 2008; Goodwin et al., 2012).